Eli Lilly | LLY - Gross Profit On Sales


Eli Lilly reported $16.22B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Abbott USD 6.65B 787M Jun/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Baxter International USD 1.14B 251M Jun/2026
Biogen USD 2.12B 307M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Drreddys Laboratories INR 43.04B 3.77B Mar/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Medtronic USD 6.36B 355M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Perrigo USD 313.9M 11.6M Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Phibro Animal Health USD 133.5M 12.6M Dec/2025
Prestige Brands USD 136.19M 10.11M Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Sanofi EUR 8.11B 343M Mar/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
Zoetis USD 1.76B 140M Jun/2026